← All trials
NCT06657703
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 21, 2024
- Primary completion
- Aug 30, 2025
- Completion date
- Jan 8, 2026
- First posted
- Oct 24, 2024
- Last posted
- Oct 24, 2024
- Enrollment
- 38
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- HC Biopharma Inc.Lead sponsor
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.